Dow Jones

38 686,32

1,51%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

GNFT

Genfit (GNFT)

Genfit SA

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:GNFT

Date	Heure	Source	Titre	Symbole	Société
29/05/2024	22h10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GNFT	Genfit SA
31/05/2023	22h44	PR Newswire (US)	Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)	NASDAQ:GNFT	Genfit SA
31/05/2023	22h16	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:GNFT	Genfit SA
05/05/2023	12h07	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:GNFT	Genfit SA
01/05/2023	22h01	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:GNFT	Genfit SA
18/04/2023	19h58	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:GNFT	Genfit SA
29/09/2022	14h35	TipRanks	H.C. Wainwright Sticks to Their Buy Rating for Genfit SA (GNFT)	NASDAQ:GNFT	Genfit SA
13/04/2022	14h55	TipRanks	Genfit SA (GNFT) Gets a Buy Rating from H.C. Wainwright	NASDAQ:GNFT	Genfit SA
14/02/2022	12h35	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:GNFT	Genfit SA
21/12/2021	11h55	TipRanks	Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Guardant Health (GH) and Genfit SA (GNFT)	NASDAQ:GNFT	Genfit SA
18/12/2021	15h51	Business Wire	Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird	NASDAQ:GNFT	Genfit SA
17/12/2021	07h00	Business Wire	Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership	NASDAQ:GNFT	Genfit SA
17/12/2021	07h00	Business Wire	Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long terme	NASDAQ:GNFT	Genfit SA
10/02/2021	12h41	TipRanks	Genfit Pops 29% Pre-Market On ‘Positive’ Data From Liver Disease Therapy Study	NASDAQ:GNFT	Genfit SA
08/06/2020	21h59	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:GNFT	Genfit SA
21/02/2020	19h44	Edgar (US Regulatory)	Amended Report of Foreign Issuer (6-k/a)	NASDAQ:GNFT	Genfit SA
27/03/2019	23h13	GlobeNewswire Inc.	Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market	NASDAQ:GNFT	Genfit SA